



PURIFICATION OF MONONUCLEAR CELLS, MONOCYTES AND POLYMORPHONUCLEAR LEUKOCYTES

- Section 10 contains a list of papers that report the use of iodixanol gradients for isolation of leukocytes indexed according to species, source (blood or tissue) and, where appropriate, analytical study.

1. Iodinated density gradient media

In the early nineteen-sixties Arne Bøyum, who was working in Oslo on the fractionation of blood leukocytes, recognized that the derivatives of triiodobenzoic acid that were being synthesized as X-ray imaging agents (for human intravenous injection) would also make ideal density gradient media for mammalian cell fractionation. The modern version of the medium that he devised for the purification of human peripheral blood mononuclear cells (PBMCs), which is marketed by Axis-Shield under the trade-name Lymphoprep™, is almost identical to that described in Boyum's seminal paper published in 1968 [1]. It contains the ionic compound sodium diatrizoate (also known as Hypaque®); its molecular structure is shown in Figure 1. Later, non-ionic derivatives, which are better tolerated by cells, were produced as X-ray imaging agents. These included iohexol (known under the commercial name Nycodenz®) in the early nineteen-eighties and about ten years later iodixanol, which is more or less a dimer of Nycodenz® (see Figure 1). Iodixanol is available commercially as a sterile 60% (w/v) solution called OptiPrep™. All of Axis-Shield's density gradient media are produced in facilities that operate under strict FDA and EU cGMP compliance and to the European Pharmacological Standard of <1.0 endotoxin unit/ml. The actual measured levels of endotoxin are regularly <0.13 units/ml. This information, together with density and osmolality data, is available on the Certificate of Analysis that accompanies each batch of medium.




Figure 1: Molecular structure of iodinated density gradient media

- Because of their use as X-ray imaging agents, these compounds have been clinically tested; no other density gradient media conform to this high standard. More information about the industrial production of these compounds is available in the Axis-Shield Density Gradient Media catalogue.

2. Density barrier isolation of human PBMCs

2a. Lymphoprep™

The isolation of human PBMCs is undoubtedly the most frequently performed of any density gradient technique; this is attested to by the many ready-made solutions produced commercially for this relatively simple separation.

- The composition of Axis-Shield's Lymphoprep™ is: 9.1% (w/v) sodium diatrizoate and 5.7% (w/v) polysaccharide; density = 1.077 ± 0.001 g/ml, osmolality = 290 ± 15 mOsm (<0.13 endotoxin units/ml).



Figure 2: Purification of human PBMCs from six donors on Lymphoprep™

- The polysaccharide, which contributes to the overall density of the medium, also aggregates the erythrocytes to enhance their rate of sedimentation.
- The standard protocol is to dilute blood with an equal volume of saline; layer 6 ml over 3 ml of Lymphoprep™ and centrifuge at 600 g for 20 min. A typical result is shown in Figure 2.
- For frequent processing of large numbers of blood samples the **Lymphoprep™ Tube** offers a time-saving option. Tubes are pre-filled with Lymphoprep™, contained below a porous plastic frit, thus permitting the diluted blood to be poured onto the frit. During centrifugation the erythrocytes pellet through the frit; displacing the medium upwards, allowing the PBMCs to band at the plasma/medium interface above the frit. The PBMCs may be recovered simply by pouring off the liquid from the tube. The procedure is illustrated in Figure 3. **Lymphoprep™ Tubes** containing 2 ml or 10 ml of Lymphoprep™ are available.




Figure 3: Purification of human PBMCs in Lymphoprep™ Tube: diagrammatic representation

2b. Nycoprep™ 1.077

There is evidence that the polysaccharide in any of the commercial PBMC isolation media can be adsorbed on to the surface of lymphocytes and affect their mitogenic stimulation [2]. Axis-Shield is the only company that provides a customized polysaccharide-free medium for the isolation of human PBMCs. Nycoprep™ 1.077 has the same density, osmolality and low endotoxin levels as Lymphoprep™; it contains 14.1% (w/v) Nycodenz®, 0.44% (w/v) NaCl, 5 mM Tricine-NaOH, pH 7.0.

2c. From OptiPrep™

The 1.077 g/ml solution for human PBMC isolation may also be prepared by dilution of 5 vol. of OptiPrep™ with 17 vol. of any suitable isoosmotic medium.

- The methodology is described in Axis-Shield Application Sheet C03 (see Section 8)

3. Flotation isolation of human PBMCs

3a. Mixer strategy

In 1990 Ford and Rickwood [3] published a method in which the plasma itself became the density barrier. A 19% (w/v) Nycodenz® solution ($\rho = 1.100$ g/ml) was added to an equal volume of whole blood to raise the density of the plasma to 1.077 g/ml. During centrifugation at 1500 g for 30 min at 20°C the erythrocytes and polymorphonuclear leukocytes (PMNs) sediment while the PBMCs float to the top and are recovered from the meniscus and the medium below it. In practice a small volume (approx. 0.5 ml) of saline is layered on top of the blood before centrifugation, so that the PBMCs band at a liquid/liquid interface rather than the liquid/air meniscus. In the modern version OptiPrep™ is simply mixed with the blood. An advantage of the method is that if the blood is mixed with the OptiPrep™ upon collection, the centrifugation may be carried out up to 24 h later. A small disadvantage is that the final density of the plasma depends on the haematocrit of the blood.

- The methodology is described in Axis-Shield Application Sheet C04 (see Section 8)

3b. Platelet-free PBMCs

A drawback of any sedimentation on to a density barrier (see Section 2) is that the platelets co-band with the PBMCs. The routine procedure to remove platelets is to dilute the interface harvest with saline and centrifuge at a speed (approx. 300 g) and a time (approx. 5 min) that will loosely pellet the PBMCs but leave most of the platelets in the supernatant. After very careful removal of the majority of the supernatant, the dilution with saline and centrifugation is repeated twice. The procedure is tedious and inefficient. A more efficient alternative is to use a second low-density barrier (see Section 4).

Platelet contamination can be avoided entirely in a barrier flotation strategy. The plasma in the blood is adjusted to 1.095 g/ml (by addition of a 40% iodixanol solution); a solution of 1.077 g/ml (OptiPrep™ diluted with buffered saline) and a small volume of saline are layered on top. The PBMCs float to the top interface; all of the other cells and platelets remain at the bottom of the tube (see Figures 4a and 4b).

- The methodology is described in Axis-Shield Application Sheet C05 (see Section 8)





Figure 4a (left): Separation of platelet-free PBMCs by flotation, 4b (right): Photomicrograph of PBMC harvest

4. Removal of human blood platelets

A simple sedimentation velocity separation was developed to prepare platelets from whole blood for functional studies. It is equally efficacious for the removal of platelets from a PBMC preparation. The PBMC harvest from a density barrier separation is diluted with saline and layered over a 1.063 g/ml solution prepared from OptiPrep™ and centrifuged as described in Figure 5. All of the PBMCs sediment to the bottom of the tube, while the platelets form a broad band just beneath the interface. The method was originally worked out using Nycodenz® [4]

- The methodology is described in Axis-Shield Application Sheet C12 (see Section 8).




Figure 5: Removal of platelets from PBMCs harvested from a 10.77 g/ml barrier.

5. Purification of monocytes from human blood

Most monocyte purification methods use a leukocyte-rich plasma (LRP) rather than whole blood. The LRP may be prepared as a buffy coat by low speed centrifugation (400 g for 10-15 min) of whole blood or by allowing the erythrocytes to aggregate and sediment at 1 g in the presence of 0.6% (w/v) polysucrose.

5a. Sedimentation on to a density barrier

Boyum [5,6] introduced a Nycodenz® density barrier ($\rho = 1.068$ g/ml) for resolving monocytes and lymphocytes from a leukocyte-rich plasma (LRP). It had a slightly raised osmolality (335 mOsm) to enhance the density difference between the monocytes and the osmotically-sensitive lymphocytes (whose density is increased preferentially). The method is very effective and the purity of the monocytes is greater than 90% but the monocytes do not form a distinct band; they are concentrated in the upper half of a broad turbid zone within the density barrier (see Figure 6). In the modern version of this method the density barrier is prepared by dilution of OptiPrep™ with a hyperosmotic buffered saline of 1.05% (w/v) NaCl, 10 mM Tricine-NaOH, pH 7.0.




Figure 6: Separation of human monocytes from a leukocyte-rich plasma (LRP) on a density barrier: M=monocytes, L=lymphocytes

- The methodology is described in Axis-Shield Application Sheet C55 (see Section 8)

5b. Flotation through a discontinuous gradient

In the alternative strategy developed by Graziani-Bowering et al [7], OptiPrep™ is added to the LRP to raise its density to approx 1.1 g/ml. The leukocytes will rapidly float to the top of this dense plasma (Figure 7:1-2) when this suspension is centrifuged. In this way the mononuclear cells initially form a narrow band at the interface between the sample and a 1.084 g/ml solution layered on top. The monocytes (because of their size and density) migrate upwards through this layer and through a second low-density barrier ($\rho=1.068$ g/ml). The smaller and denser lymphocytes tend to float more slowly, and in this way a separation between the two types of cells is effected (Figure 7:2-3). Polymorphonuclear leukocytes (granulocytes) from the LRP tend to remain at the top interface of the sample zone.




Figure 7: Isolation of human monocytes: LPR = leukocyte-rich plasma, LC = leukocytes, HBS = Hepes-buffered

- Flow cytometry analysis of the monocyte-rich band showed that only 3.4% of cells were CD3⁺ (i.e. T-cells); 1.6% of cells were CD14⁺/CD4⁺, 6.9% were CD14⁺/CD4⁺ and 84.1% were CD14⁺/CD4⁺, i.e. a total of 92.6% were identified as monocytes [7].
- The methodology is described in Axis-Shield Application Sheet C09 (see Section 8)
- The method has also been adapted to the use of whole blood in Axis-Shield Application Sheet C10

6. Purification of human polymorphonuclear leukocytes (PMNs)

6a. From whole blood [8]

Polymorphprep™ contains 13.8% (w/v) sodium diatrizoate and 8% (w/v) Dextran 500; it has a density of 1.113 g/ml, a raised osmolality of 445 mOsm. It is the only medium capable of separating PBMCs and PMNs in one step from whole blood. **The use of whole human blood is essential:** water in the dextran-aggregated erythrocytes, which sediment ahead of the leukocytes, passes into the Polymorphprep™ under the influence of the osmotic pressure gradient, effectively diluting the medium. As a consequence, the osmotic pressure inside the erythrocytes increases; thus as they continue to sediment through the medium the osmotic pressure gradient between the cells and the medium and the loss of water from the cells progressively decline. The end result is the creation of a continuous density gradient in the medium. It is in this continuous gradient that the PBMCs and PMNs are resolved (see Figure 8). The efficacy of the method relies on the use of fresh blood from healthy donors.




Figure 8: Purification of PMNs using Polymorphprep™. PBMCs = peripheral blood mononuclear cells; PMNs = polymorphonuclear leukocytes, RBCs = red blood cells. Insert right shows the typical result of a separation in a 15ml centrifuge tube from 5ml of blood and 5 ml of Polymorphprep™.

- The methodology is described in the Polymorphprep™ Application Sheet (see Section 8).

6b. From a leukocyte-rich plasma (LRP)

The LRP is best prepared from whole blood by allowing the erythrocytes to aggregate and sediment at 1 g in the presence of 0.6% (w/v) polysucrose. If this is then layered over a solution of density 1.077 g/ml (for example Lymphoprep™) and centrifuged at 600-700 g for 20 min, then the PBMCs will band at the interface and the PMNs will pellet. This is quite a common approach. However, the pelleting and consequent aggregation of PMNs at the bottom of the tube disturbs the functional integrity of the cells. Pelleting can be avoided by including a high-density cushion beneath the 1.077 g/ml layer. The easiest strategy is to prepare both layers by dilution of OptiPrep™ with a buffered saline (see Figure 9). The method is more robust than the Polymorphprep™ method; it is less dependent on the time from drawing the blood.

- The methodology is described in Application Sheet C11 (see Section 8).

7. Mononuclear cells (MCs) and neutrophils from experimental animals

7a. Using a 1.077 g/ml density barrier

Although commercial media designed for isolation of human blood PBMCs (see Section 2a) such as Lymphoprep™ or Histopaque 1.077 have been used for rodent and rabbit blood, the yields are low because lymphocytes from these species have a higher median density than those of human blood. Consequently there are some commercial media (e.g. Histopaque 1.083), which address this problem simply by raising the density of the medium from 1.077 g/ml to 1.083 g/ml. This effectively improves the yield of MCs but significantly increases the contamination from neutrophils. Bøyum et al [9] overcame this serious problem by using a 1.077 g/ml of slightly reduced osmotic pressure (265 mOsm). Lymphocytes are osmotically-sensitive, neutrophils are not; thus reduction of the osmotic pressure effectively reduces the density of lymphocytes but has no effect at all on the density of the neutrophils. A 1.077 g/ml, 265 mOsm density barrier is thus the only means of obtaining rodent and rabbit MCs in high yield without neutrophil contamination.

- The methodology has also been used for MCs from canine, porcine and bovine blood.
- The reduced osmolality barrier is no longer available commercially as NycoPrep™ 1.077A; it is however prepared very easily from OptiPrep™; the methodology is described in Application Sheet C43 (see Section 8).
- The reduced osmolality barrier is also used for the purification of MCs from a variety of animal tissues; the methodology is described in Application Sheet C40 (see Section 8).

If a leukocyte-rich plasma (LRP) is used instead of whole blood the same reduced osmolality 1.077 g/ml barrier may be used for the simultaneous isolation of neutrophils, which will pellet. The pellet will also contain erythrocytes not aggregated by the polysucrose during the preparation of the LRP. After removal of the MCs and all of the liquid above the neutrophil pellet, the latter is suspended in isotonic ammonium chloride to lyse the erythrocytes selectively. Finally the neutrophils are pelleted and resuspended in saline.

- The methodology is described in Application Sheet C45 (see Section 8).

7b. Using a mixer flotation strategy

The method described in Section 3a has also been adapted to rat, mouse and bovine blood; see Application Sheets C06, C07 and C08 respectively (see Section 8).

8. Axis-Shield technical literature

The Axis-Shield Application Sheets described in the above text may be accessed from the Index of the “Mammalian and non-mammalian cells” file either on the Axis-Shield OptiPrep™ Applications CD or from the following Axis-Shield website: www.axis-shield-density-gradient-media.com. Other relevant OptiPrep™ Application Sheets that address gradient preparation may also be accessed from the top of the Index. The Polymorphprep™ Application Sheet is also available from www.axis-shield-density-gradient-media.com




Figure 9: Purification of PMNs from an LRP. For abbreviations see legend to Figure 8

9. References

1. Boyum, A. (1968) *Isolation of mononuclear cells and granulocytes from human blood: Isolation of mononuclear cells by one centrifugation and of granulocytes by combining centrifugation and sedimentation at 1g* Scand. J. Clin. Lab. Invest., **21** (Suppl. 97), 77-89
2. Feucht, H.E., Hadam, M.R., Frank, F. and Reithmuller, G. (1980) *Efficient separation of human T lymphocytes from venous blood using PVP-coated colloidal silica particles (Percoll)* J. Immunol. Meth., **38**, 43-51
3. Ford, T. C. and Rickwood, D. (1990) *A new one-step method for the isolation of human mononuclear cells* J. Immunol. Meth., **134**, 237-241
4. Ford, T.C., Graham, J. and Rickwood, D. (1990) *A new, rapid, one-step method for the isolation of platelets from human blood* Clin. Chim. Acta, **192**, 115-120
5. Bøyum, A., Berg, T. and Blomhoff, R. (1983) *Fractionation of mammalian cells* In: Iodinated density gradient media - a practical approach (ed D. Rickwood) IRL Press at Oxford University Press, Oxford, UK, pp 147-171
6. Bøyum, A., Lovhaug, D., Tresland, L. and Nordlie, E.M. (1983) *Separation of leucocytes: improved cell purity by fine adjustments of gradient medium density and osmolality* Scand. J. Immunol., **34**, 697-712
7. Graziani-Bowering, G.M., Graham, J. and Filion, L.G. (1997) *A quick, easy and inexpensive method for the isolation of human peripheral blood monocytes* J. Immunol. Meth., **207**, 157-168
8. Ferrante, A. and Thong, Y.H. (1980) *Optimal conditions for simultaneous purification of mononuclear and polymorphonuclear leucocytes from human blood by the Hypaque-Ficoll method* J. Immunol. Meth., **36**, 109-117
9. Bøyum, A., Løvhaug, D., Tresland, I. and Nordlie, E.M. (1991) *Separation of leucocytes: improved cell purity by fine adjustments of gradient medium density and osmolality* Scand. J. Immunol., **34**, 697-712

10. Published papers reporting the use of OptiPrep™ for the purification of leukocytes

References are list alphabetically according to first author.

Monocytes from a leukocyte-rich plasma

Human

Adherence to endothelial cells

AbdAlla, S., Lothar, H., Langer, A., el Faramawy, Y. and Quitterer, U. (2004) *Factor XIIIa transglutaminase crosslinks AT₁ receptor dimers of monocytes at the onset of atherosclerosis* Cell, **119**, 343-354

Aspinall, A.I., Curbishley, S.M., Lator, P.F., Weston, C.J., Blahova, M., Liaskou, E., Adams, R.M., Holt, A.P. and Adams, D.H. (2010) *CX3CR1 and vascular adhesion protein-1-dependent recruitment of CD161 monocytes across human liver sinusoidal endothelium* Hepatology, **51**, 2030-2039

Belcher, J.D., Marker, P.H., Weber, J.P., Hebbel, R.P. and Vercellotti, G.M. (2000) *Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion* Blood, **96**, 2451-2459

Blomqvist, H.M. and Olsson, A.G. (2003) *Monocyte chemoattractant protein-1 and CC-chemokine receptor-2 in severe hypercholesterolaemia* Scand. J. Clin. Lab. Invest., **63**, 513-520

Brevig, T., Holst, B., Ademovic, Z., Rozlosnik, N., Rohrmann, J.H., Larsen, N.B., Hansen, O.C. and Kingshott, P. (2005) *The recognition of adsorbed and denatured proteins of different topographics by β_2 integrins and effects on leukocyte adhesion and activation* Biomaterials, **26**, 3039-3053

Belcher, J.D., Marker, P.H., Weber, J.P., Hebbel, R.P. and Vercellotti, G.M. (2000) *Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion* Blood, **96**, 2451-2459

Blomqvist, H.M. and Olsson, A.G. (2003) *Monocyte chemoattractant protein-1 and CC-chemokine receptor-2 in severe hypercholesterolaemia* Scand. J. Clin. Lab. Invest., **63**, 513-520

Brevig, T., Holst, B., Ademovic, Z., Rozlosnik, N., Rohrmann, J.H., Larsen, N.B., Hansen, O.C. and Kingshott, P. (2005) *The recognition of adsorbed and denatured proteins of different topographics by β_2 integrins and effects on leukocyte adhesion and activation* Biomaterials, **26**, 3039-3053

Del Conde, I., Nabi, F., Tonda, R., Thiagarajan, P., Lopez, J.A. and Kleiman, N.S. (2005) *Effect of P-selectin on phosphatidylserine exposure and surface-dependent thrombin generation on monocytes* Arterioscler. Thromb. Vasc. Biol., **25**, 1065-1070

Ferreira, A.M., Isaacs, H., Hayflick, J.S., Rogers, K.A. and Sandig, M. (2006) *The p110 δ isoform of PI3K differentially regulates β_1 and β_2 integrin-mediated monocyte adhesion and spreading and modulates diapedesis* Microcirculation, **13**, 439-456

Galetti, A., Campbell, S., Morris, J.M., Jackson, C.J., Twigg, S.M. and Gallery, E.D.M. (2004) *Monocyte adhesion to decidual endothelial cells is increased in pregnancies complicated by type 1 diabetes but not by gestational diabetes* Diabetes Care, **27**, 2514-2515

Humphries, J., Gossage, J.A., Modarai, B., Burnand, K.G., Sisson, T.H., Murdoch, C. and Smith, A. (2009) *Monocyte urokinase-type plasminogen activator up-regulation reduces thrombus size in a model of venous thrombosis* J. Vasc. Surg., **50**, 1127-1134

Ohlsson, S., Hellmark, T., Pieters, K., Sturfelt, G., Wieslander, J. and Segelmark, M. (2005) *Increased monocyte transcription of the proteinase 3 gene in small vessel vasculitis* Clin. Exp. Immunol., **141**, 174-182

Ronald, J.A., Ionescu, C.V., Rogers, K.A. and Sandig, M. (2001) *Differential regulation of transendothelial migration of THP-1 cells by ICAM-1/LFA-1 and VCAM-1/VLA-4* J. Leukoc. Biol., **70**, 601-609

Schwartz, B.R., Karsan, A., Bombeli, T. and Harlan, J.M. (1999) *A novel β_1 integrin-dependent mechanism of leukocyte adherence to apoptotic cells* J. Immunol., **162**, 4842-4848

Sneddon, A.A., McLeod, E., Wahle, K.W.J. and Arthur, J.R. (2006) *Cytokine-induced monocyte adhesion to endothelial cells involves platelet-activating factor: Suppression by conjugated linoleic acid* Biochim. Biophys. Acta, **1761**, 793-801

Ward, J.R., Francis, S.E., Marsden, L., Suddason, T., Lord, G.M., Dower, S.K., Crossman, D.C. and Sabroe, I. (2009) *A central role for monocytes in Toll-like receptor-mediated activation of the vasculature* Immunology, **128**, 58-68

Angiogenic/immune responses

Agostini, L., Martinon, F., Burns, K., McDermott, M.F., Hawkins, P.N. and Tschopp, J. (2004) *NALP3 forms an IL-1 β -processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder* Immunity, **20**, 319-325

Aittomaki, S., Pesu, M., Groner, B., Janne, O.A., Palvimo, J.J. and Silvennoinen, O. (2000) *Cooperation among Stat1, glucocorticoid receptor, and PU.1 in transcriptional activation of the high-affinity Fc γ receptor I in monocytes* J. Immunol., **164**, 5689-5697

Ammons, M.C.B., Siemsen, D.W., Nelson-Overton, L.K., Quinn, M.T. and Gauss, K.A. (2007) *Binding of pleomorphic adenoma gene-like 2 to the tumor necrosis factor (TNF)- α -responsive region of the NCF2 promoter regulates p67^{phox} expression and NADPH oxidase activity* J. Biol. Chem., **282**, 17941-17952

Cousins, S.W., Espinosa-Heidemann, D.G. and Csaky, K.G. (2004) *Monocyte activation in patients with age-related macular degeneration* Arch. Ophthalmol., **122**, 1013-1018

Filion, L.G., Matusevicius, D., Graziani-Bowering, G.M., Kumar, A. and Freedman, M. (2003) *Monocyte-derived IL12, CD86 (B7-2) and CD40L expression in relapsing and progressive multiple sclerosis* Clin. Immunol., **106**, 127-138

Filion, L.G., Graziani-Bowering, G., Matusevicius, D. and Freedman, M.S. (2003) *Monocyte-derived cytokines in multiple sclerosis* Clin. Exp. Immunol., **131**, 324-334

Hong, G., Davis, B., Khatoon, N., Baker, S.F. and Brown J. (2003) *PPAR γ -dependent anti-inflammatory action of rosiglitazone in human monocytes: suppression of TNF α secretion is not mediated by PTEN regulation* Biochem. Biophys. Res. Commun., **303**, 782-787

Li, C-Y., Chou, T-C., Lee, C-H., Tsai, C-S., Loh, S-H. and Wong, C-S. (2003) *Adrenaline inhibits lipopolysaccharide-induced macrophage inflammatory protein-1 α in human monocytes: the role of β -receptors* Anesth. Analg., **96**, 518-523

Lommatzsch, M., Schloetke, K., Klotz, J., Schuhbaeck, K., Zingler, D., Zingler, C., Schulte-Herbruggen, O., Gill, H., Schuff-Werner, P. and Virchow, J.C. (2005) *Brain-derived neurotrophic factor in platelets and airflow limitation in asthma* Am. J. Respir. Crit. Care Med., **171**, 115-120

Miller, L.A., Li, C and Hyde, D.M. (2000) *Expression of the HML-1 epitope on human monocytes is independent of α E integrin mRNA* Inflammation, **24**, 195-205

Ohlsson, S., Wieslander, J. and Segelmark, M. (2004) *Circulating cytokine profile in anti-neutrophilic cytoplasmic autoantibody-associated vasculitis: prediction of outcome* Mediators Inflamm., **13**, 275-283

Xue, M., March, L., Sambrook, P.N., Fukudome, K. and Jackson, C.J. (2007) *Endothelial protein C receptor is overexpressed in rheumatoid arthritis (RA) synovium and mediates the anti-inflammatory effects of activated protein C in RA monocytes* Ann. Rheum. Dis., **66**, 1574-1580

Bacterial infection

Horzempa, J., Tarwacki, D.M., Carlson Jr., P.E., Robinson, C.M. and Nau, G.J. (2008) *Characterization and application of a glucose-repressible promoter in Francisella tularensis* Appl. Environ. Microbiol., **74**, 2161-2170

Horzempa, J., Carlson Jr, P.E., O'Dee, D.M., Shanks, R.M.Q. and Naum G.J. (2008) *Global transcriptional response to mammalian temperature provides new insight into Francisella tularensis pathogenesis* BMC Microbiol., **8**:172

Chemotaxis

Li, Y., Nishiura, H., Tokita, K., Kouike, Y., Taniguchi, C., Iwahara, M., Nishino, N., Hamad, Y., Asakawa, M. and Yamamoto, T. (2009) *Elastin peptide receptor-directed monocyte chemotactic polysaccharides derived from seaweed sporophyll and from infectious fungus* Microb. Pathog. **45**, 423-434

Magazine, H.I., Chang, J., Goumon, Y. and Stefano, G.B. (2000) *Rebound from nitric oxide inhibition triggers enhanced monocyte activation and chemotaxis* J. Immunol., **165**, 102-107

Papaspyridonos, M., McNeill, E., de Bono, J.P., Smith, A., Burnand, K.G., Channon, K.M. and Greaves, D.R. (2008) *Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction* Arterioscler. Thromb. Vasc. Biol., **28**, 433-440

Ritter, U. and Moll, H. (2000) *Monocyte chemotactic protein-1 stimulates the killing of Leishmania major by human monocytes, acts synergistically with IFN- γ and is antagonized by IL-4* Eur. J. Immunol., **30**, 3111-3120

Dendritic cell, derived

Alvarez, Y., Municio, C., Alonso, S., San Román, J.A., Sánchez Crespo, M. and Fernández, N. (2009) *Cyclooxygenase-2 induced by zymosan in human monocyte-derived dendritic cells shows high stability, and its expression is enhanced by atorvastatin* J. Pharmacol. Exp. Ther., **329**, 987-994

Valera, I., Fernández, N., García Trinidad, A., Alonso, S., Brown, G.D., Alonso, A. and Sánchez Crespo, M. (2008) *Costimulation of dectin-1 and DC-SIGN triggers the arachidonic acid cascade in human monocyte-derived dendritic cells* J. Immunol., **180**, 5727-5736

Drug delivery (liposomes)

Qin, J., Chen, D.W., Hu, H.Y., Cui, Q., Qiao, M.X. and Chen, B.Y. (2007) *Surface modification of RGD-liposomes for selective drug delivery to monocytes/neutrophils in brain* Chem. Pharm. Bull., **55**, 1192-1197

Qin, J., Chen, D.W., Hu, H.Y., Qiao, M.X., Zhao, X.L. and Chen, B.Y. (2007) *Body distribution of RGD-mediated liposomes in brain-targeting drug delivery* Yakugaku Zasshi, **127**, 1497-1501

Immune responses see Angiogenic/immune responses

Inflammatory responses

Chaudhuri, N., Paiva, C., Donaldson, K., Duffin, R., Parker, L.C., Sabroe, I. (2010) *Diesel exhaust particles override natural injury-limiting pathways in the lung* Am. J. Physiol. Lung. Cell. Mol. Physiol. **299**, L263–L271

Chen, S.S.H., Jenkins, A.J. and Majewski, H. (2009) *Elevated plasma prostaglandins and acetylated histone in monocytes in Type 1 diabetes patients* Diabet. Med., **26**, 182–186

Oo, Y.H., Weston, C.J., Lalor, P.F., Curbishley, S.M., Withers, D.R., Reynolds, G.M., Shetty, S., Harki, J., Shaw, J.C., Eksteen, B., Hubscher, S.G., Walker, L.S.K. and Adams, D.H. (2010) *Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver* J. Immunol., **184**, 2886–2898

Papaspyridonos, M., McNeill, E., de Bono, J.P., Smith, A., Burnand, K.G., Channon, K.M. and Greaves, D.R. (2008) *Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction* Arterioscler. Thromb. Vasc. Biol., **28**, 433-440

Xue, M., March, L., Sambrook, P.N. and Jackson, C.J. (2007) *Differential regulation of matrix metalloproteinase 2 and matrix metalloproteinase 9 by activated protein C: Relevance to inflammation in rheumatoid arthritis* Arthritis Rheumatism, **56**, 2864-2874

Leishmania

Ritter, U. and Moll, H. (2000) *Monocyte chemotactic protein-1 stimulates the killing of Leishmania major by human monocytes, acts synergistically with IFN- γ and is antagonized by IL-4* Eur. J. Immunol., **30**, 3111-3120

Liver, recruitment to

Aspinall, A.I., Curbishley, S.M., Lalor, P.F., Weston, C.J., Blahova, M., Liaskou, E., Adams, R.M., Holt, A.P. and Adams, D.H. (2010) *CX3CR1 and vascular adhesion protein-1-dependent recruitment of CD161 monocytes across human liver sinusoidal endothelium* Hepatology, **51**, 2030-2039

LPS induced responses

Creery, D., Angel, J.B., Aucoin, S., Weiss, W., Cameron, W.D., Diaz-Mitoma, F. and Kumar, A. (2002) *Nef protein of human immunodeficiency virus and lipopolysaccharide induce expression of CD14 on human monocytes through differential utilization of interleukin-10* Clin. Diagnost. Lab. Immunol., **9**, 1212-1221

Widing, L., Bechensteen, A.G., Mirlashari, M.R., Vetlesen, A. and Kjeldsen-Kragh, J. (2007) *Evaluation of nonleukoreduced red blood cell transfusion units collected at delivery from the placenta* Transfusion **47**, 1481-1487

Macrophage differentiation

Alvarez, Y., Municio, C., Alonso, S., Sánchez Crespo, M. and Fernández, N. (2009) *The induction of IL-10 by zymosan in dendritic cells depends on CREB activation by the coactivators CREB-binding protein and TORC2 and autocrine PGE2* J. Immunol., **183**, 1471–1479

Carlson, P.E., Carroll, J.A., O'Dee, D.M. and Nau, G.J. (2007) *Modulation of virulence factors in Francisella tularensis determines human macrophage responses* Microb. Pathogen. **42**, 204-214

Cousins, S.W., Espinosa-Heidemann, D.G. and Csaky, K.G. (2004) *Monocyte activation in patients with age-related macular degeneration* Arch. Ophthalmol., **122**, 1013-1018

Liang, C-P., Han, S., Okamoto, H., Carnemolia, R., Tabas, I., Accili, D. and Tali, A.R. (2004) *Increased CD36 protein as a response to defective insulin signaling in macrophages* J. Clin. Invest., **113**, 764-773

Li, C-Y., Chou, T-C., Lee, C-H., Tsai, C-S., Loh, S-H. and Wong, C-S. (2003) *Adrenaline inhibits lipopolysaccharide-induced macrophage inflammatory protein-1 α in human monocytes: the role of β -receptors* Anesth. Analg., **96**, 518-523

Quesniaux, V., Erard, F. and Ryffel, B. (2010) *Adjuvant activity on murine and human macrophages* In Vaccine Adjuvants (ed. Davies, G.) Methods Mol. Biol., **626**, 117-130, Humana Press, Totowa, NJ, USA

Robinson, C.M., O'Dee, D., Hamilton, T. and Nau, G.J. (2010) *Cytokines involved in interferon- γ production by human macrophages* J. Innate Immun., **2**, 56–65

Vosper, H., Patel, L., Graham, T.L., Khoudoli, G.A., Hill, A., Macphee, C.H., Pinto, I., Smith, S.A., Suckling, K.E., Wolf, C.R. and Palmer, C.N.A. (2001) *The peroxisome proliferator-activated receptor delta promotes lipid accumulation in human macrophages* J. Biol. Chem. **276**, 44258-4426

Metalloproteinases

Bao, W., Min, D., Twigg, S.M., Shackel, N.A., Warner, F.J., Yue D.K., McLennan, S.V. (2010) *Monocyte CD147 is induced by advanced glycation end products and high glucose concentration: possible role in diabetic complications* Am. J. Physiol. Cell Physiol., **299**, C1212–C121

Ludwig, A., Berkhout, T., Moores, K., Groot, P. and Chapman G. (2002) *Fractalkine is expressed by smooth muscle cells in response to IFN- γ and TFN- α and is modulated by metalloproteinase activity* J. Immunol., **168**, 604-612

Methodology

Graziani-Bowering, G.M., Graham, J. and Filion, L.G. (1997) *A quick, easy and inexpensive method for the isolation of human peripheral blood monocytes* J. Immunol. Methods, **207**, 157-168

Nutt, J.C., Willis, C.C., Morris, J.M. and Gallery, E.D.M. (2004) *Isolating pure populations of monocytes from the blood of pregnant women: comparison of flotation in iodixanol with elutriation* J. Immunol. Methods, **293**, 215-218

Oxidation

Gauss, K.A., Bunger, P.L., Larson, T.C., Young, C.J., Nelson-Overton, L.K., Siemsen, D.W. and Quinn, M.T. (2005) *Identification of a novel tumor necrosis factor α -responsive region in the NCF2 promoter* J. Leukoc. Biol., **77**, 267-278

Gauss, K.A., Bunger, P.L., Crawford, M.A., McDermott, B.E., Swearingen, R., Nelson-Overton, L.K., Siemsen, D.W., Kobayashi, S.D., DeLeo, F.R. and Quinn, M.T. (2006) *Variants of the 5'-untranslated region of human NCF2: expression and translational efficiency* Gene, **366**, 169-179

VEGF transfection

Modarai, B., Humphries, J., Gossage, J.A., Waltham, M., Burnand, K.G., Kanaganayagam, G.S., Afuwape, A., Paleolog, E., Smith, A., Wadoodi, A. (2008) *Adenovirus-mediated VEGF gene therapy enhances venous thrombus recanalization and resolution* Arterioscler. Thromb. Vasc. Biol., **28**, 1752-1759

Virus interactions

Chehadeh, W., Bouzidi, A., Alm, G., Wattré, P. and Hober, D. (2001) *Human antibodies isolated from plasma by affinity chromatography increase the coxsackievirus B4-induced synthesis of interferon- α by human peripheral blood mononuclear cells in vitro* J. Gen. Virol., **82**, 1899-1907

Creery, D., Angel, J.B., Aucoin, S., Weiss, W., Cameron, W.D., Diaz-Mitoma, F. and Kumar, A. (2002) *Nef protein of human immunodeficiency virus and lipopolysaccharide induce expression of CD14 on human monocytes through differential utilization of interleukin-10* Clin. Diagnost. Lab. Immunol., **9**, 1212-1221

Dumont, L.J., Luka, J., van den Broeke, T., Whitley, P., Ambruso, D.R. and Elfath, M.D. (2001) *The effect of leukocyte-reduction method on the amount of human cytomegalovirus in blood products: a comparison of apheresis and filtration methods* Blood, **97**, 3640-3647

Mackewicz, C.E., Yuan, J., Tran, P., Diaz, L., Mack, E., Selsted, M.E. and Levy, J.A. (2003) *α -Defensins can have anti-HIV activity but are not CD8 cell anti-HIV factors* AIDS, **17**, F23-F32

Ovine

Berger, S.T. and Griffin, F.T. (2006) *A comparison of ovine monocyte-derived macrophage function following infection with Mycobacterium avium ssp. avium and Mycobacterium avium ssp. paratuberculosis* Immunol. Cell Biol., **84**, 349-356

Macaque

Tongaonkar, P., Tran, P., Roberts, K., Schaal, J., Osapay, G., Tran, D., Ouellette, A.J. and Selsted, M.E. (2011) *Rhesus macaque θ -defensin isoforms: expression, antimicrobial activities and demonstration of a prominent role in neutrophil granule microbicidal activities* J. Leukoc. Biol., **89**, 283–290

Mouse

Abd Alla, J., Langer, A., Elzahwy, S.S., Arman-Kalcek, G., Streichert, T. and Quitterer, U. (2010) *Angiotensin-converting enzyme inhibition down-regulates the pro-atherogenic chemokine receptor 9 (CCR9)-chemokine ligand 25 (CCL25) axis* J. Biol. Chem., **285**, 23496-23505

Monocytes (human) from whole blood

Burdo, T.H., Wood, M.R. and Fox, H.S. (2007) *Osteopontin prevents monocyte recirculation and apoptosis* J. Leukoc. Biol. **81**, 1504-1511

Goodman, R.S., Kirton, C.M., Oostingh, G.J., Schon, M., Clark, M.R., Bradley, J.A. and Taylor, C.J. (2008) *PECAM-1 polymorphism affects monocyte adhesion to endothelial cells* Transplantation, **85**, 71-477

Anwar, K., Voloshyna, I., Littlefield, M.J., Carsons, S.E., Wirkowski, P.A., Jaber, N.L., Sohn, A., Eapen, S. and Reiss, A.B. (2011) *COX-2 Inhibition and inhibition of cytosolic phospholipase A2 increase CD36 expression and foam cell formation in THP-1 cells* Lipids **46**, 131–142

Mononuclear cells (barrier sedimentation)**Blood (chicken)**

Xu, S., Xue, C., Li, J., Bi, Y. and Cao, Y. (2011) *Marek's disease virus type 1 microRNA miR-M3 suppresses cisplatin-induced apoptosis by targeting SMAD2 of the transforming growth factor beta signal pathway* J. Virol., **85**, 276-285

Blood (equine)

Ellison, S.P., Greiner, E., Brown, K.W. and Kennedy, T. (2004) *Experimental infection of horses with culture-derived Sarcocystis neurona merozoites as a model for equine protozoal myeloencephalitis* Int. J. Appl. Res. Vet. Med., **2**, 79-89

Blood (human)**Antigen-presenting cells**

Kurosaki, M., Horiguchi, S., Yamasaki, K., Uchida, Y., Motohashi, S., Nakayama, T., Sugimoto, A. and Okamoto, Y. (2011) *Migration and immunological reaction after the administration of α GalCer-pulsed antigen-presenting cells into the submucosa of patients with head and neck cancer* Cancer Immunol. Immunother., **60**, 207–215

Basophil isolation

Youssef, L.A., Pharm, B., Wilson, B.S. and Oliver, J.M. (2002) *Proteasome-dependent regulation of Syk tyrosine kinase levels in human basophils* J. Allergy Clin. Immunol., **110**, 366-373

CD34⁺ cells

Veljkovic, D.K., Rivard, G.E., Diamandis, M., Blavignac, J., Cramer-Bordé, E.M. and Hayward, C.P.M. (2009) *Increased expression of urokinase plasminogen activator in Quebec platelet disorder is linked to megakaryocyte differentiation* Blood, **113**, 1535-1542

Endocannabinoid system

Chiang, K.P., Gerber, A.L., Sipe, J.C. and Cravatt, B.F. (2004) *Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use* Hum. Mol. Genet., **13**, 2113-2119

Gene expression in exercise

Radom-Aizik, S., Zaldivar, F., Leu, S-Y. and Cooper, D.M. (2009) *Brief bout of exercise alters gene expression in peripheral blood mononuclear cells of early- and late-pubertal males* Pediatr. Res., **65**, 447–452

Radom-Aizik, S., Zaldivar, F., Leu, S. and Cooper, D.M. (2009) *A brief bout of exercise alters gene expression and distinct gene pathways in peripheral blood mononuclear cells of early- and late-pubertal females* J. Appl. Physiol., **107**, 168–175

Lung cancer patients, administration to

Motohashi, S., Nagato, K., Kunii, N., Yamamoto, H., Yamasaki, K., Okita, K., Hanaoka, H., Shimizu, N., Suzuki, M., Yoshino, I., Taniguchi, M., Fujisawa, T. and Nakayama, T. (2009) *A phase I-II study of α -galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer* J. Immunol., **182**, 2492–2501

Lymphocyte proliferation

Stechmiller, J.K., Langkamo-Henken, B., Childress, B., Herrlinger-Garcia, K.A., Hugens, J., Tian, L., Percival, S.S. and Steele, R. (2005) *Arginine supplementation does not enhance serum nitric oxide levels in elderly nursing home residents with pressure ulcers* Biol. Res. Nurs., **6**, 289-299

Natural killer cells

Ishikawa, A., Motohashi, S., Ishikawa, E., Fuchida, H., Higashino, K., Otsuji, M., Iizasa, T., Nakayama, T., Taniguchi, M. and Fujisawa, T. (2005) *A phase I study of α -galactosylceramide (KRN7000) – pulsed dendritic cells in patients with advanced and recurrent non – small cell lung cancer* Clin. Cancer Res., **11**, 1910-1917

Motohashi, S., Ishikawa, A., Ishikawa, E., Otsuji, M., Iizasa, T., Hanaoka, H., Shimizu, N., Horiguchi, S., Okamoto, Y., Fujii, S-i., Taniguchi, M., Fujisawa, T. and Nakayama, T. (2006) *A phase I study of in vitro expanded natural T killer cells in patients with advanced and recurrent non-small cell lung cancer* Clin. Cancer Res., **12**, 6079-6085

Petersen, L., Petersen, C.C., Møller-Larsen, A. and Hokland, M.E. (2010) *Short-term exposure to human cytomegalovirus-infected fibroblasts induces a proportional increase of active CD94/NKG2A⁺ natural killer cells* Hum. Immunol., **71**, 29–35

Uchida, T., Horioguchi, S., Tanaka, Y., Yamamoto, H., Kunii, N., Motohashi, S., Taniguchi, M., Nakayama, T. and Okamoto, Y. (2008) *Phase I study of α -galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer* Cancer Immunol. Immunother., **57**, 337-345

Sample processing

De Roos, B., Duthie, S.J., Polley, A.C.J., Mulholland, F., Bouwman, F.G., Heim, C., Rucklidge, G.J., Johnson, I.T., Mariman, E.C., Daniel, H. and Elliott, R.M. (2008) *Proteomic methodological recommendations for studies involving human plasma, platelets and peripheral blood mononuclear cells* J. Proteome Res., **7**, 2280-2290

Holland, N.T., Smith, M.T., Eskenazi, B. and Bastaki, M. (2003) *Biological sample collection and processing for molecular epidemiological studies* Mutat. Res., **543**, 217-234

Holland, N.T., Pfleger, L., Berger, E., Ho, A. and Bastaki, M. (2005) *Molecular epidemiology biomarkers – sample collection and processing considerations* Tox. Appl. Pharmacol., **206**, 261-268

α -Synuclein

Barbour, R., Kling, K., Anderson, J.P., Banducci, K., Cole, T., Diep, L., Fox, M., Goldstein, J.M., Soriano, F., Seubert, P. and Chilcote, T.J. (2008) *Red blood cells are the major source of alpha-synuclein in blood* Neurodegener. Dis., **5**, 55-59

T-cell infiltration

Grundtner, R., Dornmair, K., Dahm, R., Flügel, A., Kawakami, N., Zeitelhofer, M., Schoderboeck, L., Nosov, M., Selzer, E., Willheim, M., Kiebler, M., Wekerle, H., Lassmann, H. and Bradl, M. (2007) *Transition from enhanced T cell infiltration to inflammation in the myelin-degenerative central nervous system* Neuobiol. Dis., **28**, 261-275

VEGF

Kusumanto, Y.H., Dam, W.A., Hospers, G.A.P., Meijer, C. and Mulder, N.H. (2003) *Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor* Angiogenesis, **6**, 283-287

Webb, N.J.A., Watson, C.J., Roberts, I.S.D., Bottomley, M.J., Jones, C.A., Lewis, M.A., Postlethwaite, R.J. and Benchley, P.E.C. (1999) *Circulating vascular endothelial growth factor is not increased during relapses of steroid-sensitive nephrotic syndrome* Kidney Int., **55**, 1063-1071

Vitamin B₁₂ uptake

Obeid, R., Kuhlmann, M., Kirshc, C-M. and Herrmann, W. (2005) *Cellular uptake of vitamin B₁₂ in patients with chronic renal failure* Nephron Clin. Pract., **99**, c42-c48

Blood (non-human primate)

Stittelaar, K., Wyatt, L.S., de Swart, R.L., Vos, H.W., Groen, J., van Amerongen, G., van Binnendijk, R.S., Rozenblatt, S., Moss, B. and Osterhaus, A.D.M.E. (2000) *Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies* J. Virol., **74**, 4236-4243

Stittelaar, K.J., Kuiken, T., de Swart, R.L., van Amerongen, G., Vos, H.W., Niesters, H.G.M., van Schalkwijk, P., van der Kwast, T., Wyatt, L.S., Moss, B. and Osterhaus, A.D.M.E. (2001) *Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques* Vaccine, **19**, 3700-3709

Van der Kruijl, A.C., van den Burg, R., Hoyer, M.J. Gruters, R.A., Osterhaus, A.D.M.E. and Berhout, B. (2004) *SIVdrl detection in captive mandrills: are mandrill infected with a third strain of simian immunodeficiency virus?* Retrovirology, **1**:36

Blood (porcine)

Kim, S.J., Han, Y.W., Rahman, Md.M., Kim, S.B., Uyanga, E., Lee, B.M., Kim, J.H., Roh, Y.S., Kang, S.H., Kim, K., Lee, J.H., Kim, B., Park, K.I. and Eo, S.K. (2010) *Live attenuated Salmonella enterica serovar Typhimurium expressing swine interferon- α has antiviral activity and alleviates clinical signs induced by infection with transmissible gastroenteritis virus in piglets* Vaccine **28** (2010) 5031–5037

Blood (ruminant)

Imakawa, K., Nagaoka, K., Nojima, H., Hara, Y. and Christensen, R.K. (2005) *Changes in immune cell distribution and IL-10 production are regulated through endometrial IP-10 expression in the goat uterus* Am. J. Reprod. Immunol., **53**, 54-64

Nagaoka, K., Sakai, A., Nojima, H., Suda, Y., Yokomizo, Y., Imakawa, K., Sakai, S. and Christenson, R.K. (2003) *A chemokine, interferon (IFN)- γ -inducible protein 10 kDa, is stimulated by IFN- τ and recruits immune cells in the ovine endometrium* Biol. Reprod., **68**, 1413-1421

Semen (human)

Byrn, R.A. and Kiessling, A.A. (1998) *Analysis of human immunodeficiency virus in semen: indications of a genetically distinct virus reservoir* J. Reprod. Immunol., **41**, 161-176

Eyre, R.C., Zheng, G. and Kiessling, A.A. (2000) *Multiple drug resistance mutations in human immunodeficiency virus in semen but not blood of a man on antiretroviral therapy* Urology, **55**, 591xvii-591xx

Tissues (rodent)

Bone marrow

Aliotta, J.M., Pereira, M., Johnson, K.W., de Paza, N., Dooner, M.S., Puente, N., Ayala, C., Brilliant, K., Berza, D., Lee, D., Ramratnam, B., McMillan, P.N., Hixson, D.C., Josic, D. and Quesenberry, P.J. (2010) *Microvesicle entry into marrow cells mediates tissue-specific changes in mRNA by direct delivery of mRNA and induction of transcription* Exp. Hematol., **38**, 233–245

Evans, C.A., Tonge, R., Blinco, D., Pierce, A., Shaw, J., Lu, Y., Hanzah, H.G., Gray, A., Downes, C.P., Gaskell, S.J., Spooncer, E. and Whetton, A.D. (2004) *Comparative proteomics of primitive hematopoietic cell populations reveals differences in expression of proteins regulating motility* Blood, **103**, 3751-3759

Unwin, R.D., Smith, D.L., Blinco, D., Wilson, C.L., Miller, C.J., Evans, C.A., Jaworska, E., Baldwin, S.A., Barnes, K., Pierce, A., Spooncer, E. and Whetton, A.D. (2006) *Quantitative proteomics reveals posttranslational control as a regulatory factor in primary hematopoietic stem cells* Blood, **107**, 4687-4694

Whetton, A.D., Lu, Y., Pierce, A., Carney, L. and Spooncer, E. (2003) *Lysophospholipids synergistically promote primitive hematopoietic cell chemotaxis via a mechanism involving Vav1* Blood, **102**, 2798-2802

Heart

Dobaczewski, M., Xia, Y., Bujak, M., Gonzalez-Quesada, C. and Frangogiannis, N.G. (2010) *CCR5 signaling suppresses inflammation and reduces adverse remodeling of the infarcted heart, mediating recruitment of regulatory T cells* Am. J. Pathol., **176**, 2177–2187

Intestine

Wang, X., O’Gorman, M.R.G., Bu, H-F., Koti, V., Zuo, X-L. and Tan, X-D. (2009) *Probiotic preparation VSL#3 alters the distribution and phenotypes of dendritic cells within the intestinal mucosa in 57BL/10J mice* J. Nutr. **139**, 1595–1602

Zellweger, R.M., Prestwood, T.R. and , S. (2010) *Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease* Cell Host Microbe **7**, 128–139

Liver

Lian Z-X., Okada, T., He, X-S., Kita, H., Liu, Y-J., Ansari, A.A., Kikuchi, K., Ikehara, S. and Gershwin, M.E. (2003) *Heterogeneity of dendritic cells in the mouse liver: identification and characterization of four distinct populations* J. Immunol., **170**, 2323-2330

Mehal, W., Sheikh, S.Z., Gorelik, L. and Flavell, R.A. (2005) *TGF- β signaling regulates CD8+ T cell responses to high- and low-affinity TCR interactions* Int. Immunol., **17**, 531-538

Nasr, I.W., Reel, M., Oberbarnscheidt, M.H., Mounzer, R.H., Baddoura, F.K., Ruddle, N.H. and Makkis, F.G. (2007) *Tertiary lymphoid tissues generate effector and memory T cells that lead to allograft rejection* Am. J. Transplant., **7**, 1071-1079

Obhari, J.S., Oberbarnscheidt, M.H., Hand, T.W., Diggs, L., Chalasani, G. and Lakkis, F.G. (2006) *Effector T cell differentiation and memory T cell maintenance outside secondary lymphoid organs* J. Immunol., **176**, 4051-4058

Mononuclear cells (mixer flotation)

Cord blood

Elias, M., Choudhury, N. and Smit Sibinga, CTh. (2003) *Cord blood from collection to expansion : Feasibility in a regional blood bank* Indian J. Padiatr., **70**, 327-336

Blood (human)

Bouwens, M., Afman, L.A. and Müller, M. (2007) *Fasting induces changes in peripheral blood mono-nuclear cell gene expression profiles related to increases in fatty acid β -oxidation: functional role of peroxisome proliferator-activated receptor α in human peripheral blood mononuclear cells* Am. J. Clin. Nutr., **86**, 1515-1523

Hutchinson, M.R., La Vincente, S.F. and Somogyi, A.A. (2004) *In vitro opioid induced proliferation of peripheral blood immune cells correlates with in vivo cold pressor pain tolerance in humans: a biological marker of pain tolerance* Pain, **110**, 751-755

Kang, K.B., van der Zyp, A., Iannazzo, L. and Majewski, H. (2006) *Age-related changes in monocyte and platelet cyclooxygenase expression in healthy male humans and rats* Translat. Res., **148**, 289-294

Müller, T.H., Döschner, A., Schunter, F. and Scott, C.S. (1997) *Manual and automated methods for the determination of leukocyte counts at extreme low levels: comparative evaluation of the Nageotte chamber* Transfus. Sci., **18**, 505-515

Blood (ruminant)

Isen, I. and Storset, A.K. (2001) *Innate IFN- γ production in cattle in response to MPP14, a secreted protein from Mycobacterium avium subsp. paratuberculosis* Scand. J. Immunol., **54**, 305-313

Blood (rodent)

DiJoseph, J.F., Dougher, M.M., Kalyandrug, L.B., Armellino, D.C., Boghaert, E.R., Hamann, P.R., Moran, J.K. and Damle, N.K. (2006) *Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma* Clin. Cancer Res., **12**, 242-249

Houghton, J., Macera-Bloch, L.S., Harrison, L., Kim, K.H. and Korah, R.M. (2000) *Tumor necrosis factor alpha and interleukin 1 β up-regulate gastric mucosal Fas antigen expression in Helicobacter pylori infection* Infect. Immun., **68**, 1189-1195

Kang, K.B., van der Zyp, A., Iannazzo, L. and Majewski, H. (2006) *Age-related changes in monocyte and platelet cyclooxygenase expression in healthy male humans and rats* Translat. Res., **148**, 289-294

Mishra, R.S., Carnevale, K.A. and Cathcart, M.K. (2008) *iPLA2 β : front and center in human monocyte chemotaxis to MCP-1* J. Exp. Med., **205**, 347-359

Shahrara, S., Proudfoot, A.E.I., Woods, J.M., Ruth, J.H., Amin, M.A., Park, C.C., Haas, C.S., Pope, R.M., Haines, G.K., Zha, Y.Y. and Koch, A.E. (2005) *Amelioration of rat adjuvant-induced arthritis by Met-RANTES* Arthritis Rheumatism, **52**, 1907-1919

Shao, X., Rivera, J., Niang, R., Casadevall, A. and Goldman, D.L. (2005) *A dual role for TGF- β 1 in the control and persistence of fungal pneumonia* J. Immunol., **175**, 6757-6763

Wada, Y., Lu, R., Zhou, D., Chu, J., Przewloka, T., Zhang, S., Li, L., Wu, Y., Qin, J., Balasubramanyam, V., Barsoum, J. and Ono, M. (2007) *Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor* Blood, **109**, 1156-1164

Tissues (rodent)

Au-Yeung, B.B. and Fowell, D.J. (2007) *A key role for Itk in both IFN γ and IL-4 production by NKT cells* J. Immunol., **179**, 111-119

DiJoseph, J.F., Dougher, M.M., Kalyandrug, L.B., Armellino, D.C., Boghaert, E.R., Hamann, P.R., Moran, J.K. and Damle, N.K. (2006) *Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma* Clin. Cancer Res., **12**, 242-249

Ginnandrea, M., Pierce, R.H. and Crispe, I.N. (2009) *Indirect action of tumor necrosis factor-alpha in liver injury during the CD8 $^{+}$ T cell response to an adeno-associated virus vector in mice* Hepatology, **49**, 2010-2020

John, B. and Crispe, I.N. (2005) *LR-4 regulates CD8 $^{+}$ T cell trapping in the liver* J. Immunol., **175**, 1643-1650

John, B., Klein, I. and Crispe, I.N. (2007) *Immune role of hepatic TLR-4 revealed by orthotopic mouse liver transplantation* Hepatology, **45**, 178-186

Klein, I. and Crispe, I.N. (2006) *Complete differentiation of CD8 $^{+}$ T cells activated locally within the transplanted liver* J. Exp. Med., **203**, 437-447

Polakos, N.K., Klein, I., Richter, M.V., Zaiss, D.M., Giannandrea, M., Crispe, I.N. and Topham, D.J. (2007) *Early intrahepatic accumulation of CD8 $^{+}$ T cells provides a source of effectors for nonhepatic immune responses* J. Immunol., **179**, 201-210

Sanjabi, S., Mosaheb, M.M. and Flavell, R.A. (2009) *Opposing effects of TGF- β and IL-15 cytokines control the number of short-lived effector CD8 $^{+}$ T cells* Immunity **31**, 131-144

Wuensch, S.A., Pierce, R.H. and Crispe, I.N. (2006) *Local intrahepatic CD8 $^{+}$ T cell activation by a non-self-antigen results in full functional differentiation* J. Immunol., **177**, 1689-1697

Zenewicz, L.A., Yancopoulos, G.D., Valenzuela, D.M., Murphy, A.J., Karow, M. and Flavell, R.A. (2007) *Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation* Immunity, **27**, 647-659

Web:

www.axis-shield-density-gradient-media.com

Axis-Shield

PO Box 6863 Rodelokka
N-0504 Oslo
Norway

Phone: +47 24 05 60 00

Fax: +47 24 05 60 10

Email: bjh@axis-shield.com or
john@jgrescon.fsbusiness.co.uk



Excellence in Separations

DENSITY GRADIENT MEDIA

A graphic for an Axis-Shield advertisement. It features two test tubes, one with a dark liquid and one with a lighter, yellowish liquid, set against a background of a ruler and chemical structures. The chemical structures are complex, featuring a central benzene ring with various substituents, including iodine atoms, hydroxyl groups, and amide linkages. The ruler has markings at 20, 30, and 40. The text 'Axis-Shield has the solutions' is written in a stylized font at the bottom. The Axis-Shield logo, which consists of a stylized figure holding a shield, is located in the bottom right corner.

Axis-Shield has the solutions

